Table 4.
Hematology summaries (d 0–21) by treatment.
| Treatment group | ||||||
|---|---|---|---|---|---|---|
| 1 (NC) | 2 (ZnO3-NC) | 3 (ZnO3-2) | 4 (ZnO6-4) | 5 (ZnO6) | ||
| HCT d 0 | 0.401 ± 0.008 | 0.395 ± 0.012 | 0.400 ± 0.006 | 0.432 ± 0.011 | 0.368 ± 0.049 | |
| HCT d 21 | 0.369 ± 0.016 | 0.369 ± 0.008 | 0.381 ± 0.011 | 0.371 ± 0.008 | 0.354 ± 0.021 | |
| Mean ∆ HCT* | −0.021 | −0.031 | −0.021 | −0.057 | −0.021 | p < 0.001 |
| Hb d 0 | 117 ± 3 | 114 ± 3 | 117 ± 3 | 124 ± 3 | 109 ± 14 | |
| Hb d 21 | 111 ± 4 | 111 ± 2 | 114 ± 3 | 110 ± 2 | 104 ± 7 | |
| Mean ∆ Hb* | −3.0 | −3.6 | −3.6 | −10.5 | −6.8 | p = 0.006 |
Hb = hemoglobin (g/L); HCT = hematocrit (L/L); NC = negative control. Values represent mean ± SEM.
*
Values represent matched pairs analysis (Wilcoxon signed rank test). A significant decrease was observed for both HCT and Hb over 21 d for all groups; however, significant differences between treatments were not observed.